Dermatology

Jasper Therapeutics has released new, positive findings on the use of briquilimab, a novel antibody therapy targeting KIT (CD117), in patients with CSU.

Investigators look at the ways in which CSU impacts family members supporting those with CSU, using the Family Dermatology Life Quality Index (FDLQI).

This quarterly recap highlights some of the most notable news and developments in the dermatology space from Q4 in 2025.

Investigators observed disparities in race with persistent chemotherapy-induced alopecia among women with breast cancer.

This summary of headlines in the field of dermatology summarizes some of the most notable news covered in December 2025.

The data may help to guide informed decision-making related to dupilumab use and management of severe atopic dermatitis in infants and young children.

In this end-of-year reel, HCPLive has showcased several key highlights from the Skin of Color Savvy podcast in 2025.

Catch up on news headlines highlighted in the dermatology space by HCPLive in 2025 with this Year in Review.

Catch up on some of the biggest alopecia areata news headlines covered by HCPLive from 2025 with this ‘Year in Review’ summary.

A review found increased anxiety, depression, social anxiety, and perceived stress among individuals with androgenetic alopecia compared with those without the condition.

To stay informed, catch up on some of the most notable alopecia areata news headlines from 2025 with our Year in Review.

Catch up on some of the most significant headlines in atopic dermatitis news coverage from 2025 with our Year in Review.

Catch up on some of the most notable headlines in psoriasis news coverage from 2025 with our Year in Review.

In this analysis, investigators assessed the effects of any weight-loss intervention, behavioural or pharmacological, on the severity of psoriasis as well as quality-of-life outcomes.

Stay updated with the latest healthcare breakthroughs, including FDA news and phase 3 trial readouts, in this week's essential news roundup.

This study explored the potential impact of body mass index (BMI) and smoking on patients’ risk of developing hidradenitis suppurativa.

In a new post hoc analysis of 4 pivotal clinical studies in atopic dermatitis and prurigo nodularis, nemolizumab was shown to improve symptoms.

Topical steroid withdrawal remains a controversial topic in the dermatology field, given the lack of necessary data.

Cosmo Pharmaceuticals released pivotal phase 3 findings on clascoterone treatment, a potential first-in-class medication designed to target androgenetic alopecia.

Investigators observed rapid, sustained clinical benefits after using vixarelimab in patients living with prurigo nodularis.

The highly selective oral TYK2 inhibitor met coprimary endpoints for sPGA 0/1 and PASI 75 at week 16 versus placebo in the phase 3 Latitude studies.

In this episode, a panel of dermatologists join to discuss the impact of the Boards University educational initiative for residents and early-career physicians.

Topline findings from the phase 2b REZOLVE-AA trial highlight the efficacy of rezpegaldesleukin in severe-to-very-severe alopecia areata.

This December 16 episode features a discussion of winter skin concerns and seasonal dermatologic challenges impacting patients with skin of color.

Investigators highlighted patterns of addictive behavior among those with chronic skin diseases in European tertiary dermatology centers.